CIAS
DNLI icon

Capital Investment Advisory Services’s Denali Therapeutics DNLI Stock Holding History

Capital Investment Advisory Services’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-6
Closed – – 732
2019
Q3 		$0 Buy
+6
New +$115 ﹤0.01% 1389

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Capital Investment Advisory Services's DNLI Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Denali Therapeutics (DNLI) in Q4 2019, closing a stake of 6 shares.

Capital Investment Advisory Services first reported a position in DNLI in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 108 funds tracked by Wall St. Rank hold DNLI as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining Denali Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 6 Denali Therapeutics shares in Q4 2019.
  • Capital Investment Advisory Services first reported a position in Denali Therapeutics in Q3 2019 and held it in 1 quarter.
  • Capital Investment Advisory Services's Denali Therapeutics position peaked at $0 in Q3 2019.
  • 108 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.